NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Anika Therapeutics, Inc. (ANIK) Stock Analysis

Anika Therapeutics, Inc. (ANIK) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANIK

$20.60

+$0.16 (+0.78%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANIK with… →

ANIK Key Statistics

As of Oct 21, 2026
Trading
Open
$20.48
Previous Close
$20.44
Day's Range
20.22–20.61
52-Week Range
9.01–22.88
Volume
51.29K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.21
Valuation
Market Cap
$275.69M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
21.68
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.15
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.23
Financials (FY)
Revenue (FY)
$112.82M−5.91%
Net Income (FY)
−$10.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.14%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.38M
1-Year Return
+110.63%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
108.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANIK closed at $20.60, +110.63% over 1 year.

Anika Therapeutics, Inc. (ANIK) has a market capitalization of $275.69M.

In fiscal 2025, ANIK reported revenue of $112.82M.

ANIK Stock Return by Calendar Year

Anika Therapeutics, Inc. (ANIK) 10-year return: what $10,000 became

1 year
$10,000 $21,063
+110.63%
5 years
$10,000 $4,954
−50.46%
10 years
$10,000 $4,719
−52.81%

If you had invested $10,000 in Anika Therapeutics, Inc. (ANIK) 10 years ago, at the close on October 21, 2016, it would have been worth $4,719 at the close on October 21, 2026: −52.81% in total, −7.23% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+114.36%
2025−41.62%
2024−27.36%
2023−23.45%
2022−17.39%
2021−20.84%
2020−12.71%
2019+54.27%
2018−37.66%
2017+10.11%
2016 (partial year)+3.05%

As of October 21, 2026.

ANIK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$112.82M−$10.88M−9.6%
2024$119.91M−$56.39M−47.0%
2023$120.79M−$82.67M−68.4%
2022$113.83M−$14.86M−13.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$112.82M$63.81M−$11.05M−$10.88M−9.6%
2024$119.91M$76.00M−$5.10M−$56.39M−47.0%
2023$120.79M$82.53M$844.00K−$82.67M−68.4%
2022$113.83M$73.22M$3.67M−$14.86M−13.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ANIK Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricANIKDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.282.109% above
Profit margin−3.14%−8.14%5.0 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Anika Therapeutics, Inc. (ANIK) at $275.69M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 235.

The 52-week range on file runs from $9.01 to $22.88. ANIK last closed at $20.60 on October 21, 2026. That is +$0.16 (+0.78%) against the previous close. The latest close sits 128.63% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $112.82M. That is −5.91% against the prior fiscal year, when revenue was $119.91M. The same year closed with a net loss of $10.88M. Profit margin runs at −3.14%. That is 5 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.23.

Across the 4 fiscal years on file, revenue moves from $113.83M in 2022 to $112.82M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 21.68. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.15. The price-to-sales ratio is 2.28. On price-to-sales that is 8.81% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +110.63%. Measured over 10 years, that is −7.23% a year compounded. The reported beta is 0.21. Daily returns over the trailing 10 years annualize to a volatility of 47.95%.

Growth & Income

The record shows no dividend for ANIK.

So far in 2026 the total return is +114.36%. The strongest complete calendar year on file is 2019 at +54.27%; the weakest is 2025 at −41.62%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Anika Therapeutics, Inc. (ANIK) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anika Therapeutics, Inc. ANIK $275.69M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Anika Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Visit website →